content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <!-- Generated by Workiva -->
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001778307</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001744659</issuerCik>
        <issuerName>Akero Therapeutics, Inc.</issuerName>
        <secFileNumber>001-38944</secFileNumber>
        <issuerAddress>
          <com:street1>601 Gateway Boulevard</com:street1>
          <com:street2>Suite 350</com:street2>
          <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>650-487-6488</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Andrew Cheng</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>President, CEO and Director</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>J.P. Morgan Securities LLC</name>
          <address>
            <com:street1>390 Madison Avenue, 6th Floor</com:street1>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10017</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>120000</noOfUnitsSold>
        <aggregateMarketValue>6843600</aggregateMarketValue>
        <noOfUnitsOutstanding>69799148</noOfUnitsOutstanding>
        <approxSaleDate>01/27/2025</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <acquiredDate>12/21/2020</acquiredDate>
        <natureOfAcquisitionTransaction>Open market purchase</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>See nature of acquisition</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>120000</amountOfSecuritiesAcquired>
        <paymentDate>04/18/2023</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <securitiesSoldInPast3Months>
        <sellerDetails>
          <name>Andrew Cheng</name>
          <address>
            <com:street1>C/o Akero Therapeutics, Inc.</com:street1>
            <com:street2>601 Gateway Boulevard, Suite 350</com:street2>
            <com:city>South San Francisco</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94080</com:zipCode>
          </address>
        </sellerDetails>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <saleDate>11/01/2024</saleDate>
        <amountOfSecuritiesSold>108366</amountOfSecuritiesSold>
        <grossProceeds>3438289</grossProceeds>
      </securitiesSoldInPast3Months>
      <securitiesSoldInPast3Months>
        <sellerDetails>
          <name>Andrew Cheng</name>
          <address>
            <com:street1>C/o Akero Therapeutics, Inc.</com:street1>
            <com:street2>601 Gateway Boulevard, Suite 350</com:street2>
            <com:city>South San Francisco</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94080</com:zipCode>
          </address>
        </sellerDetails>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <saleDate>12/02/2024</saleDate>
        <amountOfSecuritiesSold>25000</amountOfSecuritiesSold>
        <grossProceeds>802252</grossProceeds>
      </securitiesSoldInPast3Months>
      <remarks>The shares covered by this filing were acquired through open market purchases between 12/21/20 and 04/18/23 and will be sold within three months from the date of this filing.</remarks>
      <noticeSignature>
        <noticeDate>01/27/2025</noticeDate>
        <planAdoptionDates>
          <planAdoptionDate>08/16/2024</planAdoptionDate>
        </planAdoptionDates>
        <signature>/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Andrew Cheng</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4580}]
text: 144
  0001778307
  XXXXXXXX
  LIVE
  0001744659
  Akero Therapeutics, Inc.
  001-38944
  601 Gateway Boulevard
  Suite 350
  South San Francisco
  CA
  94080
  650-487-6488
  Andrew Cheng
  President, CEO and Director
  Common Stock
  J.P. Morgan Securities LLC
  390 Madison Avenue, 6th Floor
  New York
  NY
  10017
  120000
  6843600
  69799148
  01/27/2025
  NASDAQ
  Common Stock
  12/21/2020
  Open market purchase
  See nature of acquisition
  N
  120000
  04/18/2023
  Cash
  N
  Andrew Cheng
  C/o Akero Therapeutics, Inc.
  601 Gateway Boulevard, Suite 350
  South San Francisco
  CA
  94080
  Common Stock
  11/01/2024
  108366
  3438289
  Andrew Cheng
  C/o Akero Therapeutics, Inc.
  601 Gateway Boulevard, Suite 350
  South San Francisco
  CA
  94080
  Common Stock
  12/02/2024
  25000
  802252
  The shares covered by this filing were acquired through open market purchases between 12/21/20 and 04/18/23 and will be sold within three months from the date of this filing.
  01/27/2025
  08/16/2024
  /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Andrew Cheng